Clinical Research Directory

Inclusion Criteria: * Consent to participate in the study * Age \>18 years * Performance status (PS) 0-1 * Availability of biological samples for multi-omic profiling * Availability of radiological images for radiomic assessments * Patients with metastatic disease, i.e., stage IV (except for melanoma, where stage II/III patients eligible for adjuvant therapy may also be considered) * Patients eligible for targeted therapy and/or immunotherapy * Patients with aggressive neoplasms, including melanoma, non-small cell lung carcinoma (NSCLC), colon carcinoma (BRAF-mutated, MSI), triple-negative breast cancer, ovarian cancer, and cholangiocarcinoma. Exclusion Criteria: * Previous line of immunotherapy or targeted therapy * Previous radiotherapy at the sites of the most recent diagnostic biopsy * Most recent diagnostic biopsy performed \>24 months before enrollment * Absence of measurable lesions * Presence of active or untreated brain metastases or leptomeningeal carcinomatosis